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ABSTRACT The K+ current KI sets the resting potential in cardiac cells. Here we report that isoproterenol (ISO), a prototypical
agonist, increases inactivation of jKI This action of ISO on jKI is mimicked by permeant analogues of cAMP but is not blocked
by the blockers propranolol and pindolol or the a blockers prazosin or yohimbine. We suggest that this novel action of ISO
may contribute to pacemaker activity in the Purkinje strand and be mediated through a class of receptors different from
classical $'s or a's.
INTRODUCTION METHODS
Isoproterenol is a potent a agonist which increases both
the strength and frequency of cardiac contractions. These
effects of isoproterenol are largely mediated through
increases in calcium current and pacemaker current
( 1-3). The changes in these two membrane currents occur
through the activation of A adrenoceptors, because both
are blocked by the ,B blocker propranolol. Additional
actions of isoproterenol on cardiac K+ currents include an
increase in delayed rectifier current, an increase in
background K+ conductance, and a change in the kinetics
of inactivation of the transient outward current (4-7).
These actions of isoproterenol also involve the activation
of d adrenoceptors and also are blocked by propranolol.
We report below a novel action of isoproterenol to
inactivate the inwardly rectifying K+ conductance, iKj, in
canine cardiac Purkinje myocytes. This action of isopro-
terenol to inactivate iKI is mimicked by permeant ana-
logues of cAMP which shift the relationship between
inactivation of iKj and membrane potential in the positive
direction along the voltage axis. Surprisingly, this action
of isoproterenol is not blocked by propranolol up to 10
,gM, nor is it blocked by the a, blocker prazosin, or the a2
blocker yohimbine. This novel action of isoproterenol is of
interest because it presents evidence for modulation of iKj,
an important cardiac potassium conductance. These re-
sults also suggest that a novel mechanism may couple
isoproterenol to intracellular levels of cAMP. A presenta-
tion of some of this work was made to the British
Physiological Society (8).
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Our experiments were performed on isolated canine Purkinje myocytes
acutely dissociated from the Purkinje fibers as previously described
(9-11). We employed the whole cell voltage clamp technique with
pipettes ranging in resistance from 1.5 to 3 Mg before sealing. The
currents were recorded with the axopatch 2A amplifier in most cases
with series resistance compensation. The pipette was filled with a
solution containing in millimolar: KCI 140, NaCl 10, MgCl2 2, CaCl2 1,
EGTA 1 1, ATP 1, GTP 0. 1, and Hepes KOH 10, all buffered to a final
pH of 7.2. The superfusing Tyrode solution contained in millimolar:
NaCl 140, KCI 5.4 or 10.0, MgCl2 1.8, CaCl2 0.5 or 1.5, glucose 5.5, and
Hepes NaOH 5, all buffered to a final pH of 7.4. The temperature at
which the experiments were carried out was 35 ± lOC. Stock solutions of
isoproterenol, propranolol, prazosin, and yohimbine were prepared in
distilled water and subsequently diluted in the perfusate. 500 gM/liter
ascorbic acid was added to the stock solution containing isoproterenol to
prevent oxidation. Dibutyryl cAMP (dBcAMP) and chlorophenyl-
thiocAMP (CPTcAMP) were directly dissolved in the saline at the
concentrations indicated.
RESULTS
Fig. 1 a illustrates our basic finding. When a canine
Purkinje myocyte is hyperpolarized from a holding poten-
tial of -50 mV to a potential negative to Ek there is large
increase of inward current due to activation of the
inwardly rectifying K+ current ijo. In the presence of
isoproterenol (ISO) 1 ,uM the same hyperpolarization
results in the activation of iK, which is followed by a
pronounced inactivation. The enhanced inactivation of iy
is readily reversed upon washout of ISO. ISO caused
increased inactivation of iKI in just over 60% (24 of 39) of
cells studied.
ISO is known to alter many cardiac conductances by
stimulating adenylyl-cyclase and elevating the basal lev-
els of cAMP (12). We decided to examine whether the
inactivation of iKI was also mediated by cAMP. To
investigate this alternative we employed two permeable
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FIGURE 1 ISO and cAMP analogues enhance iKI inactivation. (a)
Traces recorded before (o), during (*), and after (A) perfusion with 1
,uM ISO. K. = 10 mM. (b) Effect of perfusion of CPTcAMP 1 mM.
Ko = 5.4 mM. The symbols have the same meaning as in a. Exp. s 025-1,
302-1.
analogues of cAMP, dibutyryl cAMP (dBcAMP, 0.5-2
mM), and cholorophenylthiocAMP (CPTcAMP, 0.5-1
mM), which were dissolved in our superfusing solution.
Both analogues of cAMP were effective in inducing
inactivation of iKl, quite similar to that obtained with ISO
(Fig. 1 a). An example of these results is given in Fig. 1 b,
where CPTcAMP 1 mM was employed. Permeable ana-
logues of cAMP increased inactivation of iKI in 70% (31 of
44) of cells studied.
Recent investigations of iKI in ventricular myocytes
have demonstrated that inactivation of iKi is voltage
dependent, being far more prominent at more hyperpolar-
ized potentials (13, 14). ISO is known to shift the gating
of at least one cardiac membrane current which activates
on hyperpolarization, if, to more positive potentials on the
voltage axis (2, 3). We therefore examined whether the
increased inactivation of iyj corresponded to a positive
shift of the inactivation versus voltage curve on the
voltage axis. The protocol we employed was first reported
by Biermans et al. (14) and assumes that the dominant
conductance change responsible for the jump in inward
current is iKI. We confirmed this assumption by applying
3-5 mM Ba2+, a blocker of iK1, which reduced the inward
jump on hyperpolarization from -40 to -120 by >80%
in four cells. Also, no time-dependent increase in outward
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FIGURE 2 Inactivation curves measured in the presence and in the
absence ofcAMP analogues at different external K concentrations. The
method used to construct the curves is illustrated in the inset. From brief
(200-300 ms) hyperpolarizing pulses, we estimated the value of instan-
taneous current by fitting the decay of iKI with a single or double
exponential, and then we extrapolated the fitted curve to zero time. P
represents the ratio of the value of the current at the end of the pulse
(isochronal, iich) to the extrapolated instantaneous current (i,na,) and
provides an estimation of the degree of iKI inactivation at different
voltages. Notice that cAMP analogues cause the curves to move in a
positive direction along the voltage axis and that the amount of this shift
is greater at lower K,, concentrations. (a) K, = 5.4 mM; Exp. 005-4. (b)
Ko = 10 mM; Exp. 004-6. (0) Control; (+) 0.5 mMdBcAMP. We
performed this experiment in a total of eight cells, four bathed in 5.4
mM and four in 10mM K+, and we used either dBcAMP or CPTcAMP
at concentrations ranging between 0.5 and 2 mM/liter. Under these
conditions we obtained an average shift of the inactivation curve of 33
mV in 5.4 K+ and 16 mV in 10mM K+.
current was observed in Ba2+-Tyrode, confirming that the
inactivation process we observed involved iKc. Our results
examining the relationship between inactivation and volt-
age are illustrated in Fig. 2. We employed Tyrode's
solution containing either 10 or 5.4 mM K+ and com-
pared the control solution with that containing dBcAMP
at a concentration of 0.5 mM/liter. There was a large
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positive shift of the relationship between inactivation and
voltage for both solutions, however, the half inactivation
level was shifted further in 5.4 than in 10 mM K+ (see
legend to Fig. 2).
We next examined the receptor type through which
ISO exerted its effects. Our initial hypothesis was that the
inactivation of iKl was exerted via classical d adrenocep-
tors, because ISO is a prototypical agonist and cAMP is
the known second messenger through which activation
exerts its effects (15). To test this hypothesis we applied 1
,MM propranolol which blocks all classical cardiac
adrenoceptors. One sample result is illustrated in Fig. 3 a.
In this experiment we employed a two-pulse protocol:
first, a hyperpolarization to observe iKI followed after a
brief pulse to - 60 mV by a depolarization to observe the
calcium current. We employed this protocol to demon-
strate the difference between the effect of ISO on jKI and
that on other cardiac membrane currents. On application
of ISO, there is an increase in the instantaneous jump in
current on hyperpolarization. This was sometimes ob-
served and may correspond to the increase in background
K+ conductance previously reported by Gadsby (6). This
conductance change is thought not to be mediated through
iKI ISO also induces the inactivation of iKI which we have
illustrated in Fig. 1 a. On depolarization ISO induces the
well-known increase in the magnitude of the calcium
current. Next propranolol (1 AM) was added to the
perfusing medium. It is clear that propranolol was able to
reverse the effect on the background K+ conductance as
well as the increase in Ca2+ current, but not the inactiva-
tion of 'KI This concentration of propranolol or lower has
been shown to reverse other effects of A agonists on
cardiac membrane currents (16, 17). Essentially the same
result was obtained in the presence of a higher concentra-
tion of propranolol (10 ,M) or when pindolol (1 ,uM) was
substituted for propranolol (data not shown). It seems
therefore unlikely that the ISO effect on iK1 is mediated
through either #, or (2 adrenoceptors.
Because a activation is known to reduce a background
K+ conductance in Purkinje myocytes (9), the next step
we undertook was to check whether ISO was exerting its
effect through a adrenoceptors. A typical result in this
series of experiments is shown in Fig. 3 b. In this case ISO
was applied in the presence of the a blockers prazosin
(a1, 1 MuM) and yohimbine (a2, 0.1 uM), as well as the
blocker propranolol (1 MuM). We did not find substantial
differences in another experiment where prazosin and
yohimbine were used at concentrations of, respectively, 2
and 1 MuM. Prazosin at 1 MuM is known to block the
phenylephrine-induced decrease in background K+ con-
ductance in Purkinje myocytes (9). We chose the highest
concentration of the a2 blocker yohimbine without direct
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FIGURE 3 Neither classical a or ,B receptor antagonists are able to
block ISO action on iKI. (aa) A two-pulse protocol was used to activate iCa
in addition to 'KI. Propranolol (1 AM) is able to reverse the ISO-induced
increase of iCa and background non-iK, K current (7) but not the
inactivation of iKI. (0) Control, (O) ISO 1 MAM, (*) ISO 1 AM +
propranolol 1 MM, (A) recovery. Exp. 302-10. (b) ISO effect on iKI
persists when a blockers are added in the presence of, blockers. (0)
Control, (*) ISO 1 MM + propranolol 1 ,uM + prazosin 1 AM +
yohimbine 0.1 ,uM, (A) recovery. Exp. 321-1. In another experiment
(321-2) before testing ISO we perfused the cells with solutions contain-
ing only the a or ,B antagonists for up to 4 min, and detected no effects of
any sort. Afterwards, we proceeded with a protocol as the one reported
above and found analogous results.
membrane effects 10-7 M (18) and then also tried a
concentration 10-fold higher, 1 MM. There is little infor-
mation on effective concentrations for a2 antagonism in
heart, but in human platelets where most a receptors are
a2, isoproterenol is a very poor agonist and the concentra-
tions of yohimbine we employed would block binding of
isoproterenol to the receptor (19). It is evident from this
data that even in a circumstance in which all the known a
and adrenoceptors should be blocked by their antago-
nists the ISO-induced increase in iKI inactivation could
not be reversed.
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DISCUSSION
The results presented above are significant for two rea-
sons. First, we have demonstrated that the background
conductance iKI is subject to modulation. Second, some
evidence is given supporting the idea that this regulation
initiated by the prototypical ,B agonist ISO may not occur
via f1 or f#2 adrenoceptors. We will discuss each of these
findings in turn.
ISO increases calcium current, pacemaker current, the
K+-selective delayed rectifier, and a non-iKi K conduc-
tance. It also induces a novel inward current at plateau
potentials (20-22). Our report presents the evidence for a
direct action of this hormone on the background conduc-
tance iKl. It is also the first definitive demonstration of
modulation of iKI. The shift in the inactivation versus
voltage curve mediated by cAMP is less pronounced in 10
mM K+ than it is in 5.4 mM K+. This larger shift at
physiologic K+ implies that iKl may inactivate positive as
well as negative to EK. If iKI inactivated positive to EK, it
would produce a slow, time-dependent decrease in out-
ward current. This time-dependent decrease in outward
current would sum with the inward background current,
and the hyperpolarization activated inward if to produce a
net inward current. The net inward current would drive
the membrane toward threshold. Thus, if iKI inactivated
positive to EK, the Purkinje pacemaker rate would in-
crease.
Neither, nor a antagonists were effective in blocking
the inactivation of iKI induced by ISO. This is surprising
for two reasons. First, ISO is the classic f, agonist, and
second, cAMP is the second messenger of d activation.
Sometimes we found the blockers increased the inactiva-
tion of iKIl Occasionally, propranolol or pindolol could also
lead to a similar time-dependent decrease of the current.
cAMP is known to be the second messenger for the
adrenergic stimulation of ica and its permeant analogues
have been shown here to be able to mimic the ISO effect
on iKl. In this context, the inability of propranolol to
reverse the effect of ISO on iKI while fully antagonizing
the drug action on iCa is puzzling. Our data so far do not
enable us to answer this question, but we can suggest two
possible explanations. Either, the two channels may
exhibit different sensitivities to cAMP concentration, or
cAMP compartmentalization may exist. If compartmen-
talization exists, it would mean that activation of normal
f3 adrenoceptors would not give rise to a sufficient increase
in [cAMP] locally to activate our response. High concen-
trations of permeant analogues ofcAMP might, however,
reach the relevant compartment. Furthermore, having
used permeant analogues of cAMP dissolved in the
external solution, we cannot even completely rule out the
possibility that these substances act at a different site than
ISO on the cell membrane, yet produce analogous effects.
Recently the existence of "atypical" ,B adrenoceptors
has been reported. These receptors exist in various tissue
types (adipocytes, smooth muscle cells, heart) (23-25).
Binding and functional studies of this new class of
receptors have demonstrated that they respond differently
than f31 and ,B2 adrenoceptors to either d antagonists
and/or partial agonists. In fact, they show a 10- to
100-fold decreased sensitivity to propranolol. In the heart
it has been demonstrated that nonconventional partial :
agonists such as pindolol give rise to a biphasic response
whose low-sensitivity component is not blocked by specific
1/,B2 antagonists (23-27). In adipocytes coupling of the
atypical ,B adrenoceptor to adenylyl-cyclase (28) has been
demonstrated. Furthermore, a gene has been recently
isolated that may encode for this atypical ,B3 adrenoceptor
(29). In this same study the authors present data from
transfection experiments that demonstrate that the prod-
uct of this gene is coupled to adenylyl-cyclase and exhibits
low affinity to standard d blockers.
Although we have not even demonstrated that an
external receptor is required, and indeed many com-
pounds inactivate ion currents by directly blocking chan-
nels (30, 31), the possibility exists that our novel effect of
ISO on 'Ki reported above may be mediated through this
new class of adrenoceptors.
Although much remains to be examined, it is clear that
the background K+ conductance iKI in the Purkinje
myocyte is hormonally controlled and that isoproterenol
may act on the heart in a manner other than classical:
adrenoceptors activation.
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